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BACKGROUND: We analysed whether the level of human epidermal growth factor receptor-2 (HER-2) amplification significantly
influenced either pathological complete response (pCR) or recurrence-free survival (RFS) and overall survival (OS) after trastuzumab-
based neoadjuvant therapy.
METHODS: In all, 99 patients with an HER-2-amplified breast tumour treated with trastuzumab-based neoadjuvant therapy were
included. Tumours were classified as low amplified (LA; 6–10 signals per nuclei) or highly amplified (HA; 410 signals). Pathological
response was assessed according to Chevallier’s classification (pCR was defined as grade 1 or 2). Median follow-up lasted 46 months
(6–83). Cox uni- and multivariate analyses were performed.
RESULTS: In all, 33 tumour samples were LA and 66 were HA. The pCR in HA tumours was significantly higher than in LA tumours
(55% vs 24%, P¼0.005), whereas no association was found between the pCR rate and tumour stage, grade or hormone receptor
status. In multivariate analysis, the pathological nodal status (P¼0.005) and adjuvant trastuzumab (P¼0.037) were independently
associated with RFS, whereas the level of HER-2 amplification nearly reached statistical significance (P¼0.057). There was no
significant difference between LA and HA tumours for OS (P¼0.22, log-rank).
CONCLUSION: The level of HER-2 gene amplification significantly influenced pCR but not RFS or OS in non-metastatic breast cancer
treated with trastuzumab-based neoadjuvant therapy. However, RFS in patients with HA tumours tended to be shorter.
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The human epidermal growth factor receptor-2 (HER-2) gene is
amplified in 10–26% of human breast cancers (Gown et al, 2008).
HER-2 gene amplification is associated with the over-expression of
the HER-2 protein in 495% of cases (Wolff et al, 2007). Both
HER-2 over-expression and HER-2 gene amplification have been
correlated with poor clinical outcome (Slamon et al, 1987;
Kallioniemi et al, 1991; Press et al, 1997). The HER-2 status is
also a strong predictor of a clinical benefit from HER-2-targeted
therapy, such trastuzumab (Herceptin; Roche, Neuilly-sur-Seine,
France), a humanised monoclonal antibody directed against the
external domain of HER-2 protein (Yamauchi et al, 2001). Several
randomised trials have proved the efficacy of trastuzumab in
metastatic (Slamon et al, 2001; Marty et al, 2005) and adjuvant
(Piccart-Gebhart et al, 2005; Romond et al, 2005; Joensuu et al,
2006; Smith et al, 2007) settings for HER-2-positive breast cancer
in terms of response rate, recurrence rate and a decrease in
mortality. In the neoadjuvant setting, trastuzumab in association
with chemotherapy had also shown a clinical benefit in terms of
pathological complete response (pCR; Van Pelt et al, 2003; Buzdar
et al, 2005; Coudert et al, 2006, 2007; Gianni et al, 2007).
American Society of Clinical Oncology/College of American
Pathologists (ASCO/CAP) guidelines recommend using either
immunohistochemistry (IHC) assays for initial evaluation of
HER-2 status followed by reflex testing by fluorescence in situ
hybridisation (FISH) of some IHC categories or FISH in initial
testing (Wolff et al, 2007). The level of over-expression of HER-2
protein with IHC assays is a known predictive factor of response to
trastuzumab (Slamon et al, 2001) and we have previously shown a
positive correlation between the level of HER-2 amplification
assessed by FISH and the rate of pCR to trastuzumab-based
neoadjuvant treatment (Arnould et al, 2007). However, the
relationship between the level of HER-2 amplification and the
outcome of patients given neoadjuvant trastuzumab remains
unclear.
Received 9 June 2010; revised 31 August 2010; accepted 9 September
2010
*Correspondence: Dr S Guiu; E-mail: sguiu@cgfl.fr
British Journal of Cancer (2010) 103, 1335–1342
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThe aim of this study was to determine whether the level
of HER-2 gene amplification using FISH assays significantly
influenced recurrence-free survival (RFS) and overall survival
(OS) in non-metastatic breast cancer treated with trastuzumab-
based neoadjuvant therapy.
MATERIALS AND METHODS
Patients
Breast biopsies from 116 patients, who had received neoadjuvant
trastuzumab in combination with chemotherapy for locally
HER-2-positive breast cancer were retrospectively collected from
19 centres in France. All of the patients provided written, informed
consent for their tissue material and clinical data to be centrally
collected and used for research purposes. This study was approved
by our institutional review board.
The patients were aged from 26 to 76 years (mean, 46.6 years)
and had histologically confirmed, unilateral, unicentric, non-
metastatic, HER-2-positive (in IHC) invasive ductal breast
carcinoma. Most of the patients were treated in the frame-
work of two open-label phase II clinical trials: GETN(A)-1
(n¼63; Coudert et al, 2007) and TAXHER-S01 (n¼21; Coudert
et al, 2006). The remaining patients (n¼32) had an equivalent
preoperative regimen to that used in the TAXHER-S01 trial.
The 63 patients included in the GETN(A)-1 trial had received
weekly neoadjuvant trastuzumab (4mgkg
 1 loading dose followed
by 2mgkg
 1) in combination with docetaxel (75mgm
 2) and
carboplatin (area under the curve of six) every 3 weeks for six
cycles. Adjuvant trastuzumab was also administered in responding
patients. The 21 patients included in the TAXHER-S01 trial
had received the same preoperative schedule of trastuzumab
in association with docetaxel (100mgm
 2) every 3 weeks for six
cycles, but no adjuvant trastuzumab was scheduled in this study.
Additional patients (n¼32) received trastuzumab every 3 weeks
(8mgkg
 1 loading dose followed by 6mgkg
 1) instead of weekly
trastuzumab (Leyland-Jones et al, 2003) and adjuvant trastuzumab
was also administered.
In all patients, 3 weeks after the last administration of
neoadjuvant trastuzumab, tumours were surgically removed and
pCR was assessed according to Chevalliers’classification: pCR was
defined as no evidence of carcinoma either in the breast or in
the lymph nodes, without (grade 1) or with (grade 2) in situ
carcinoma. In accordance with institutional practices, adjuvant
hormone therapy in patients with hormone receptor-positive
tumours and adjuvant radiotherapy were mandatory.
HER-2 status
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were initially tested IHC 3þ or 2þ for HER-2 status. For all of the
patients in this study, HER-2 status was re-analyzed centrally using
both IHC and FISH assays by an experienced pathologist who was
blinded to patient information, including the original IHC test results.
HER-2 status in IHC was evaluated with A485 polyclonal
antibody (Dako, Glostrup, Denmark) or 4B5 monoclonal antibody
(Ventana Medical Systems Inc., Tucson, AZ, USA) on the
BenchMark XT system (Ventana Medical Systems Inc.): biopsies
were graded according to the HercepTest (Dako) scoring system
(0þ,1þ,2þ,o r3þ).
FISH analyses were carried out using the HER-2 Probe (Oncor,
Gaithersburg, MD, USA) and BenchMark XT system. For each
biopsy, HER-2 signals were counted in X60 tumour cell nuclei and
the mean HER-2 signals per nuclei was calculated. The level of
HER-2 amplification in tumours was classified as follows: no
amplified (NA; mean, o6 signals per nuclei), low amplified (LA;
mean, 6–10 signals per nuclei), or highly amplified (HA; mean,
410 signals per nuclei or uncountable because of clusters of signals).
The cutoff of 10 gene copies per nuclei to distinguish between LA
and HA was chosen because it is the same as that proposed with
chromogenic in situ hybridisation and also because above this cutoff,
it is almost impossible to count signals precisely because of clusters
and small aggregates. Borderline tumours (mean between four and
eight signals per nuclei) were analysed by double-color FISH using a
HER-2-gene-specific probe and a centromeric probe for chromo-
some 17 (PathVysion HER-2 DNA Probe kit, Vysis-Abbott, Abbott
Park, IL, USA) to determine HER-2 amplification. In these cases,
HER-2 amplification was defined by a ratio of HER-2 to chromo-
some 17 centromeric signals (HER-2/CEP17) of X2.2 (Wolff et al,
2007). All the tumours with X6 HER-2 signals per nuclei had a
HER-2/CEP17 ratio X2.2 and therefore, were amplified tumours. All
the tumours with o6 HER-2 signals per nuclei had a HER-2/CEP17
ratio p1.8 and thus, were NA tumours.
Only patients with centrally confirmed HER-2 amplification
were finally included in this study to evaluate pathological
response rate (Figure 1). For RFS and OSs, NA tumours were also
included.
Statistical analysis
Qualitative variables were described using frequency and percen-
tages. w
2 and Fisher’s exact tests were used to compare patient or
tumour characteristics according to the level of HER-2 amplifica-
tion with FISH assays (NA, LA, and HA). For these analyses,
Bonferroni adjustments were carried out to prevent inflation of
type one error (the significant level was 0.016 for 3 comparisons).
Associations between tumour size, tumour grade, hormone–receptor
status, level of HER-2 amplification, and the presence or absence of pCR
were evaluated using univariate and multivariate logistic regression.
To take into account the trial effect (GETN(A)-1, TAXHER-S01, and
GFLCC database), analyses were adjusted for this factor.
The median follow-up was calculated using the reverse Kaplan–
Meier method. Recurrence-free survival was defined as the time
from the date of histology to the date of the first recurrence of
breast cancer at any site or death from any cause. Surviving
patients without recurrence were censored at the last follow-up.
The OS was defined as the time from the date of histology to death
from any cause. Survival distributions were estimated with the
TAXHER-S01
Trial
33 Patients
GETN(A)-1
Trial
70 Patients
Database
GFLCC
32 Patients
19 Patients with
FISH not available
FISH available
116 Patients
17 Patients with no
HER-2 amplification
HER-2 amplification
99 Patients
20 Patients TAXHER-S01
51 Patients GETN(A)-1
28 Patietns GFLCC
Figure 1 Flow chart of the study. Abbreviations: GFCLCC, Georges–
Franc¸ois Leclerc Cancer Center database; FISH, fluorescence in situ
hybridisation
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Univariate (RFS and OS) and multivariate (RFS) Cox proportional
hazards models stratified on the trial were fitted to test for an
association between classical prognostic variables, the level of
HER-2 amplification, pCR, adjuvant trastuzumab, and RFS or OS.
Given the small number of events, multivariate analysis for OS was
not performed. Akaike information criterion was computed for the
goodness of fit for multivariate models and Harrell’s C-statistic for
discrimination (a Harrell’s C-index¼0.5 indicates no predictive
discrimination and a Harrell’s C-index¼1.0 indicates perfect
separation of patients) for each variable and for final multivariate
Cox models. The multivariate models were internally validated
using bootstrapping (100 replications). P-values were two-tailed
and considered significant when less than 0.05. All analyses were
performed using Stata V11 software (StataCorp LP, College Station,
TX, USA).
RESULTS
Patients and tumours
Baseline patient and tumour characteristics are summarised in
Table 1. In all, 99 (85%) tumours were considered amplified after
central FISH analyses, among which 33 were classified as LA
tumours and 66 HA tumours. There were no significant differences
between these two groups in terms of tumour stage, nodal status,
hormone receptor status, or treatment given. The HA tumours had
a higher histological grade than the LA tumours (P¼0.01).
Analysis of pCR
According to Chevallier’s classification (Table 2), 44 (44.5%)
patients had a pCR, whereas 55 (55.5%) had no or only a partial
response. In univariate logistic analysis, only the level of HER-2
amplification (FISH) was related to pCR (P¼0.005). In multi-
variate analysis, this variable was independently associated with
pCR (P¼0.024), whatever the trial (P¼0.632).
Recurrence-free survival according to HER-2 amplification
Median follow-up was 46-months (range, 6–83 months). Local or
regional recurrences occurred in six patients (two HA tumours,
two LA tumours, two NA tumours); one of these had a pCR.
Metastatic recurrence (alone or with locoregional recurrence)
occurred in 18 patients (14 HA tumours, 2 LA tumours, 2 NA
tumours) among whom 5 had an initial pCR. Three patients died
without a diagnosis of recurrent disease.
Table 1 Patient and tumour characteristics according to the level of HER-2 amplification
Characteristic
Total
(n¼116)
NA
(FISH; n¼17)
LA
(FISH; n¼33)
HA
(FISH; n¼66)
P (3 groups;
Fisher exact test)
P (NA vs LA/HA;
Fisher exact test)
p (LA vs HA)
(Fisher exact test)
Mean age 46.6 46.6 48.5 45.6
(Range), year (26.5–76.4) (32–62) (29–76.4) (26.5–66)
Tumour stage 0.699 0.474 0.710
T1 16 (14%) 3 (18%) 4 (12%) 9 (14%)
T2 73 (63%) 12 (70%) 19 (58%) 42 (64%)
T3–T4 27 (23%) 2 (12%) 10 (30%) 15 (22%)
Nodal status 0.330 0.358 0.363
N0 55 (47%) 11 (65%) 12 (36%) 32 (49%)
N1 59 (51%) 6 (35%) 20 (61%) 33 (50%)
N2 2 (2%) 0 1 (3%) 1 (1%)
Tumour grade 0.057 0.890 0.010
SBR1 5 (4%) 1 (6%) 0 4 (6%)
SBR2 57 (49%) 9 (53%) 23 (70%) 25 (38%)
SBR3 47 (41%) 6 (35%) 10 (30%) 31 (47%)
Unknown 7 (6%) 1 (6%) 0 6 (9%)
Hormone receptor status 0.072 0.017 0.782
Positive 68 (59%) 13 (76%) 20 (61%) 35 (53%)
Negative 43 (37%) 2 (12%) 12 (36%) 29 (44%)
Unknown 5 (4%) 2 (12%) 1 (3%) 2 (3%)
Neoadjuvant treatment 0.315
a 0.145
a 0.670
a
TDC 63 (54%) 12 (70%) 18 (55%) 33 (50%)
TD 53 (46%) 5 (30%) 15 (45%) 33 (50%)
Central IHC score o0.001 o0.001 0.003
1+ 10 (8%) 10 (59%) 0 0
2+ 11 (10%) 6 (35%) 5 (15%) 0
3+ 95 (82%) 1 (6%) 28 (85%) 66 (100%)
Pathological response o0.001
a 0.003
a 0.004
a
pCR 45 (39%) 1 (6%) 8 (24%) 36 (55%)
Non-pCR 71 (61%) 16 (94%) 25 (76%) 30 (45%)
Adjuvant trastuzumab 0.769 0.557 0.872
a
No 32 (28%) 6 (35%) 9 (27%) 17 (26%)
Yes 84 (72%) 11 (65%) 24 (72%) 49 (74%)
Abbreviations: FISH¼fluorescence in situ hybridization; HA¼highly amplified tumours; IHC¼immunohistochemisry; LA¼low-amplified tumours; NA¼no amplified tumours;
non-pCR¼absence of complete pathological response; pCR¼pathological complete response; SBR¼Scarff–Bloom–Richardson; TD¼trastuzumab–docetaxel;
TDC¼trastuzumab–docetaxel–carboplatin.
aw
2-test. Values in bold: Po0.05.
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(P¼0.145, log-rank test; Figure 2A), or according to the HER-2
copy number (P¼0.313, log-rank test; Figure 2B) or the level of
HER-2 amplification (P¼0.161, log-rank test). In the univariate
Cox analysis, the level of HER-2 amplification was not significantly
associated with RFS (Table 3), whereas the pathological nodal
status (HR¼3.247 (CI 95%, 1.396–7.552), P¼0.006) and adjuvant
trastuzumab treatment (HR¼0.157 (CI 95%, 0.045–0.539),
P¼0.003) were. In multivariate analysis, pathological nodal status
and adjuvant trastuzumab were independently associated with
RFS, whereas the level of HER-2 amplification nearly reached
statistical significance (HR¼2.819 (CI 95%, 0.970–8.197),
P¼0.057). Internal validation using bootstrapping confirmed the
results only for the pathological nodal status.
There was no significant difference in RFS according to both
pCR and level of HER-2 amplification (P¼0.09, log-rank test).
However, the subgroup of HA tumours without pCR had a
significantly shorter RFS than did the other subgroups (P¼0.01,
log-rank test; Figure 2C).
Overall survival according to amplification of HER-2
During follow-up, 11 patients, including 8 with a metastatic
recurrence (6 HA tumours, 2 LA tumours), died. There was no
significant difference between NA, LA, and HA tumours subgroups
for OS (P¼0.111, log-rank test; Figure 3) or between LA and HA
tumours subgroups (P¼0.22, log-rank test). With Cox univariate
analysis, only tumour stage (HR¼0.158 (CI 95%, 0.039–0.636),
P¼0.034) and pathological nodal status (HR¼7.118 (CI 95%,
1.864–27.177), P¼0.004) were significantly associated with OS,
whereas the level of HER-2 amplification was not (HR¼1.974 (CI
95%, 0.413-9.425), P¼0.394).
DISCUSSION
Systemic neoadjuvant therapy is the treatment of choice for
locally advanced or inflammatory breast cancer. It also facilitates
breast conservation in selected patients with operable disease
(Kaufmann et al, 2006). For patients with HER-2-positive breast
Table 2 Univariate and multivariate logistic regression for predictive factors of pathological complete response
pCR
Univariate analysis
pCR
Multivariate analysis Bootstrapping
a
No/yes No/yes
N¼99 OR 95% CI PN ¼92 OR 95% CI P 95% CI P
Tumour stage 0.714 0.537 0.691
T1 8/5 1 — 7/4 1
T2 32/29 1.168 (0.311–4.387) 31/27 1.478 (0.290–7.529) (0.009–228.220)
T3–T4 15/10 0.781 (0.166–3.675) 14/9 0.791 (0.125–4.998) (0.004–162.119)
Study 0.570
GETN(A)-1 28/23 1
TAXHER-S01 13/7 0.602 (0.408–1.181)
GFLCC 14/14 1.182 (0.725–1.464)
Tumour grade 0.083 0.247 0.534
SBR1 3/1 1 — 3/1 1
SBR2 32/16 1.476 (0.140–15.613) 31/16 2.407 (0.217–26.645) (0–35 700 000)
SBR3 18/23 3.987 (0.361–44.019) 18/23 4.761 (0.423–53.593) (0–69 800 000)
Unknown 2/4
Study 0.706
GETN(A)-1 28/23 1
TAXHER-S01 13/7 1.043 (0.943–1.324)
GFLCC 14/14 1.523 (0.423–1.544)
Hormone receptor 0.299 0.166 0.250
Negative 20/21 1 — 19/21
Positive 33/22 0.626 (0.271–1.445) 33/19 0.496 (0.184–1.338) (0.150–1.638)
Unknown 2/1
Study 0.572
GETN(A)-1 28/23 1
TAXHER-S01 13/7 0.686 (0.500–1.230)
GFLCC 14/14 1.302 (0.589–1.500)
Amplification (FISH) 0.005 0.024 0.086
LA 25/8 1 — 24/8 1
HA 30/36 3.862 (1.508–9.892) 28/32 3.190 (1.162–8.759) (0.848–12.006)
Study 0.520 0.632 0.631
GETN(A)-1 28/23 1 26/21 1
TAXHER-S01 13/7 0.590 (0.354–1.193) 13/7 0.894 (0.220–3.632) (0.181–4.412)
GFLCC 14/14 1.188 (0.727–1.451) 13/12 1.584 (0.533–4.712) (0.560–4.482)
Abbreviations: CI¼confidence interval; FISH¼fluorescence in situ hybridisation; GFCLCC¼Georges–Franc¸ois Leclerc Cancer Center database; HA¼highly amplified tumours;
LA¼low-amplified tumours; N¼number; OR¼odds ratio; pCR¼pathological complete response; SBR¼Scarff–Bloom–Richardson.
a100 replications. Values in bold:
Po0.05.
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scancer (IHC 3þ and/or FISH positive), the addition of
trastuzumab to chemotherapy increases pCR rates (Buzdar et al,
2005; Gianni et al, 2007). We confirm in this larger study our
previous results (Arnould et al, 2007) regarding the positive
correlation between the level of HER-2 amplification determined
by FISH and the rate of pCR after trastuzumab-based neoadjuvant
therapy. Indeed, we report 55 vs 24% (P¼0.005) of pCR in the
subgroup of HA vs LA tumours, respectively. In light of these
results, the level of HER-2 amplification could be a useful tool to
decide whether to administer neoadjuvant therapy and could
therefore also increase the rate of conservative surgery. However,
this interesting predictive factor needs to be validated in further
larger studies. Indeed, our results contrast with those of a smaller
series in a neoadjuvant setting, in which response did not correlate
with the level of HER-2 gene amplification measured by FISH
(Buzdar et al, 2007); this study concerned 45 patients receiving
paclitaxel followed by 5-fluorouracile, epirubicin, and cyclopho-
sphamide (FEC) with concurrent trastuzumab. Conversely, our
results are consistent with those observed in 57 patients treated
with trastuzumab plus chemotherapy (mainly paclitaxel) for a
HER-2-positive metastatic breast cancer, in which a clinical
objective response was significantly correlated with the level of
amplification of HER-2 in FISH (Giuliani et al, 2007).
To date there are no data suggesting another mechanism than
HER-2 gene amplification to explain the over-expression of the
HER-2 protein. Consequently, both IHC and FISH can be used to
determine HER-2 status and the benefit of trastuzumab in breast
cancer (Wolff et al, 2007). In this study, after centralised analyses,
10 (8%) tumours were subsequently scored IHC 1þ (no pCR was
observed in this subgroup, data not shown). This highlights
the modest inter-laboratory reproducibility of IHC results. This
observation is in line with a recent critical review of the ASCO/CAP
guidelines (Sauter et al, 2009), which concluded that inherent
technical properties strongly argue for primary HER-2
FISH testing. Furthermore, although IHC and FISH have shown
high concordance in some studies, reproducibility remains
insufficient in others (Paik et al, 2002; Roche et al, 2002; Mass
et al, 2005). In our study, 6 out of 11 (55%) tumours with an IHC
score of 2þ were finally considered NA with the FISH assay
(with only one pCR) and the patient with a 3þ tumour in IHC,
which was NA in FISH did not benefit from trastuzumab (data not
shown).
Currently, 52 weeks of adjuvant trastuzumab are recommended
for the treatment of HER-2-positive breast cancer with a high risk
of relapse. This regimen has improved both RFS and OS (Piccart-
Gebhart et al, 2005; Romond et al, 2005; Smith et al, 2007; Slamon
et al, 2009). Several trials in progress are comparing this standard
with a shorter exposure to trastuzumab: 9 weeks as in the SOLD
study (NCT00593697) and the Short HER study (NCT00629278) or
26 weeks (PHARE study). In a recently published study, a brief
course of trastuzumab (9 weeks) administered concomitantly
with docetaxel followed by three cycles of FEC tended to improve
RFS but not OS, compared with the same regimen without
trastuzumab (Joensuu et al, 2009). In our study, adjuvant
trastuzumab, administered in addition to the 18 pre-operative
injections, significantly improved RFS (P¼0.003). All these results
are not in favour of lightening adjuvant trastuzumab. The above
mentioned studies should resolve this question.
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Figure 2 Recurrence-free survival according to the pathological response (A), the HER-2 copy number (B) and both pathological response and level of
HER-2 amplification (C; Kaplan–Meier estimate). Abbreviations: HA, highly amplified tumours; LA, low-amplified tumours; NA, no amplified tumours;
pCRþ, pathological complete response; pCR , absence of pathologiccal complete response.
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marker of outcome after neoadjuvant chemotherapy. Indeed, in
several large trials with anthracycline and/or taxanes-based
neoadjuvant therapy, RFS and OS rates were significantly
improved when pCR had been achieved (Fisher et al, 1998; Kuerer
et al, 1999; Guarneri et al, 2006). These studies were performed
before the assessment of HER-2 status and the use of trastuzumab.
In more recent studies with trastuzumab-based neoadjuvant
therapy, the association between pCR and RFS has been in-
conclusive, sometimes statistically associated (Buzdar et al, 2007),
but sometimes not (Hurley et al, 2006; Shimizu et al, 2009) as was
the case in our study, despite a long follow-up. This prognostic
factor thus remains controversial.
To our knowledge, this is the first study to report the outcome of
patients after trastuzumab-based neoadjuvant therapy according
to the level of HER-2 amplification in FISH. Although the increase
in the number of HER-2 gene copies had a significant positive
impact on the pCR rate, there was no significant difference
between HA tumours (410 HER-2 gene copies per nuclei) and LA
tumours (6–10 HER-2 gene copies per nuclei) for either RFS or OS
after a median follow-up of 46 months. However, RFS tended to be
Table 3 Univariate and multivariate Cox analysis of predictive factors of recurrence-free survival
Recurrence or death
Univariate analysis Multivariate analysis Bootstrapping
a
No/yes, N¼99 HR 95% CI P HR, N¼98 95% CI P 95% CI P
Tumour stage 0.116 0.471 0.978
T1 7/6 1 — 1 —
T2 47/14 0.446 (0.160–1.241) 0.642 (0.181–2.279) (0.007–56.910)
T3–T4 22/3 0.215 (0.048–0.972) 0.344 (0.062–1.911) (0–6 160 872)
Tumour grade 0.260
SBR1 2/2 1 —
SBR2 39/9 0.279 (0.058–1.351)
SBR3 31/10 0.414 (0.082–2.076)
Unknown 4/2
Hormone receptor 0.175
Negative 28/13 1 —
Positive 46/9 0.547 (0.229–1.308)
Unknown 2/1
Pathological nodal status 0.006 0.005 0.022
Negative 59/12 1 — 1 —
Positive 16/11 3.247 (1.396–7.552) 3.928 (1.524–10.127) (1.219–12.659)
Unknown 1/0
Amplification (FISH) 0.199 0.057 0.883
LA 28/5 1 — 1 —
HA 48/18 1.918 (0.710–5.180) 2.819 (0.970–8.197) (0–2 667 202)
pCR 0.161
No 40/15 1 —
Yes 36/8 0.523 (0.212–1.293)
pCR and FISH 0.146
No+HA 19/11 1 —
No+LA 21/4 0.385 (0.120–1.228)
Yes+HA 29/11 0.401 (0.148–1.090)
Yes+LA 7/1 0.204 (0.025–1.669)
Adjuvant Trastuzumab 0.003 0.037 0.779
No 14/12 1 1
Yes 62/11 0.157 (0.045–0.539) 0.214 (0.050–0.914) (0–10 456.280)
Harrell’s C-statistic 0.7745
AIC 137
Abbreviations: AIC¼Akaike information criterion; CI¼confidence interval; FISH¼fluorescence in situ hybridisation; HA¼highly amplified tumours; HR¼hazard ratio;
LA¼low-amplified tumours; N¼number; pCR¼pathological complete response; SBR¼Scarff–Bloom–Richardson.
a100 replications. Values in bold: Po0.05.
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Figure 3 Overall survival according to the HER-2 copy number
(Kaplan–Meier estimate). Abbreviations: HA, highly amplified tumours;
LA, low-amplified tumours; NA, no amplified tumours.
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sbetter in the HER-2 LA group (P¼0.057). A large population-
based cohort, treated before the use of trastuzumab, had already
shown that OS in breast cancer was not significantly different
according to the level of HER-2 amplification, for patients with a
HER-2/CEP17 ratio 42.2 (Jensen et al, 2008). Since the era of
trastuzumab therapy, the link between the level of HER-2
amplification and the outcome of patients has been investigated
only in the metastatic and adjuvant settings. A retrospective anal-
ysis was performed in 33 patients with HER-2-positive metastatic
breast cancer receiving trastuzumab (Gullo et al, 2009): patients
with a high HER-2/CEP17 ratio had shorter time-to-progression
and OS than did those with lower ratios (Gullo et al, 2009),
although the difference did not reach statistical significance,
probably because of the sample size and the relatively short follow-
up. Dowsett et al (2009) analyzed whether the degree of HER-2
amplification (HER-2 gene copy number and HER-2/CEP17 ratio)
influenced the clinical outcome in patients with HER-2-positive
breast cancer randomised in the two HERA trial (Piccart-Gebhart
et al, 2005) arms with or without 1 year of trastuzumab after
adjuvant chemotherapy. Although there was an apparent trend
towards shorter disease-free survival with increasing HER-2 gene
copy numbers or increasing HER-2 FISH ratios, the differences
were not statistically significant. However, in this study, the
median follow-up was only 2 years.
In conclusion, the level of HER-2 gene amplification using FISH
assays significantly influenced pCR but neither RFS nor OS in
non-metastatic breast cancer treated with trastuzumab-based
neoadjuvant therapy. However, the subgroup of patients with HA
tumours (410 signals per nuclei) tended to have a shorter RFS.
This result suggests that a high level of HER-2 amplification could
be a poor prognostic factor even though it was associated with a
good initial sensitivity to trastuzumab. Further larger and longer
studies are needed to confirm this hypothesis.
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